Literature DB >> 16386017

Sporadic methicillin resistance in community acquired Staphylococcus aureus in Mozambique.

Daniela Ceccarelli1, José Mondlane, Marco Sale, Anna M Salvia, Elena Folgosa, Piero Cappuccinelli, Mauro M Colombo.   

Abstract

This study reports the drug resistance and clonal relationship of 24 Staphylococcus aureus community acquired isolates from patients attending Maputo Central Hospital, Mozambique, during one year (2002-2003). All the isolates produced beta-lactamase, six strains were resistant to tetracycline alone, three were resistant to erythromycin alone and one was resistant to trimethoprim-sulfamethoxazole; 11 were susceptible to all other drugs tested. Only one strain showed a multiple resistance pattern, including methicillin resistance. To investigate the clonal relationships we applied the ERIC AP-PCR and the SmaI PFGE RFLP methods. Overlapping drug resistances with these two molecular profiles, no significant correlation was obtained. The emergence of methicillin resistance in a multiple resistant strain is of great concern for resistance spreading surveillance in Mozambique.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16386017

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  2 in total

1.  Antimicrobial drug resistance trends of bacteremia isolates in a rural hospital in southern Mozambique.

Authors:  Inácio Mandomando; Betuel Sigaúque; Luis Morais; Mateu Espasa; Xavier Vallès; Jahit Sacarlal; Eusébio Macete; Pedro Aide; Llorenç Quintò; Tacilta Nhampossa; Sónia Machevo; Quique Bassat; Clara Menéndez; Joaquim Ruiz; Anna Roca; Pedro L Alonso
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

2.  Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  Jörg J Ruhe; Anupama Menon
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.